{"paper_id":"6ccb5dc5-d69e-4be1-be82-25a42d5dc994","body_text":"Multi-layered genetic approaches to identify approved\ndrug targets\nMarie C. Sadler 1,2,3,*, Chiara Auwerx1,2,3,4, Patrick Deelen5,6, Zolt´an Kutalik 1,2,3,*\n1University Center for Primary Care and Public Health, Lausanne, Switzerland\n2Swiss Institute of Bioinformatics, Lausanne, Switzerland\n3Department of Computational Biology, University of Lausanne, Lausanne, Switzerland\n4 Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland\n5 University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands\n6 Oncode Institute, Utrecht, The Netherlands\n*Corresponding author: marie.sadler@unil.ch, zoltan.kutalik@unil.ch\n1\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \nNOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.\n\nAbstract\nDrugs targeting genes that harbor natural variations associated with the disease the drug is in-\ndicated for have increased odds to be approved. Various approaches have been proposed to iden-\ntify likely causal genes for complex diseases, including gene-based genome-wide association stud-\nies (GWAS), rare variant burden tests in whole exome sequencing studies (Exome) or integration of\nGWAS with expression/protein quantitative trait loci (eQTL-GWAS/pQTL-GWAS). Here, we compare\ngene-prioritization approaches on 30 common clinical traits and benchmarked their ability to recover\ndrug target genes defined using a combination of five drug databases. Across all traits, the top pri-\noritized genes were enriched for drug targets with odds ratios (ORs) of 2.17, 2.04, 1.81 and 1.31 for\nthe GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods, respectively. We quantified the perfor-\nmance of these methods using the area under the receiver operating characteristic curve as metric,\nand adjusted for differences in testable genes and data origins. GWAS performed significantly better\n(54.3%) than eQTL (52.8%) and pQTL-GWAS (51.3%), but not significantly so against the Exome ap-\nproach (51.7% vs 52.8% for GWAS restricted to UK Biobank data). Furthermore, our analysis showed\nincreased performance when diffusing gene scores on gene networks. However, substantial improve-\nments in the protein-protein interaction network may be due to circularity in the data generation process,\nleading to the node (gene) degree being the best predictor for drug target genes (OR = 8.7, 95% CI\n= 7.3-10.4) and warranting caution when applying this strategy. In conclusion, we systematically as-\nsessed strategies to prioritize drug target genes highlighting promises and potential pitfalls of current\napproaches.\n2\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nIntroduction1\nDrugs whose targets have genetic support were found to be more likely to succeed in clinical trials [1, 2].2\nAlthough multiple methods have been proposed to establish such genetic support, leveraging genetic3\ndata to find disease genes and ultimately drug targets has proven to be challenging [3, 4, 5, 6]. The4\nmost straightforward approach maps genome-wide association studies (GWASs) signals to the closest5\ngenes with more sophisticated methods incorporating linkage disequilibrium (LD) structure and gene6\nannotation information to compute gene scores [7, 8, 9]. Over the past decade, large-scale molecular7\nquantitative trait loci (mQTL) datasets facilitated the discovery of disease mechanisms and the identifi-8\ncation of potential new drug targets [10, 11, 12, 13, 14, 15]. Several methods, including Mendelian ran-9\ndomization studies, transcriptome-wide association studies and colocalization methods have integrated10\nexpression and protein QTL data with GWAS studies to pinpoint likely causal genes for complex traits11\nand diseases [16, 17, 18, 19, 20, 21, 22]. More recently, the availability of high-throughput sequencing12\ndata enabled the discovery and analysis of rare variants and their aggregated effects to reveal gene-13\ndisease associations [23, 24]. Whole exome sequencing (WES) in the UK Biobank (UKBB) showed that14\ngenes prioritized this way are 3.6 times more likely to be targets of drugs approved by the Food and15\nDrug Administration (FDA) [25].16\n17\nGenes prioritised by GWASs, mQTL-GWAS integration methods and WES burden tests may not be18\ndrug targets themselves, but up- or downstream of those in pharmacological pathways. Propagating19\ngene prioritization scores on networks has proven to be a promising approach to identify known drug20\ntarget genes [26, 27, 28, 29, 30]. Starting from seed genes (i.e., prioritized disease-associated genes),21\nnetwork connectivity can identify neighbouring genes that strongly interact with disease genes, but lack22\na direct genetic evidence that explain their therapeutic effect. Gene networks can be derived from lit-23\nerature or high-throughput experiments and thus are prone to yield very different results when used for24\n(seed) gene score diffusion [31].25\n26\nHere, we took a comprehensive approach to examine the contribution of each method component27\n3\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nto the success of drug target prioritization. First, we focused on four different approaches to prioritise28\n(seed) genes: 1) LD-aware gene score computation from the largest GWASs with full publicly available29\nsummary statistics (Pascal [9]); 2) Mendelian Randomisation (MR) combining tissue-wide expression30\nQTLs and GWAS (eQTL-GWAS); 3) MR combining plasma protein QTL with GWAS (pQTL-GWAS);31\n4) UKBB WES burden tests (Exome). We then used three different networks to diffuse the seed32\ngene scores: 1) STRING protein-protein interaction (PPI) network [32]; 2) an RNA-seq co-expression33\nnetwork [33]; 3) the FAVA network [34]. All 12 combinations of the four seed generating methods and the34\nthree networks were applied to thirty traits (Figure 1) using five different reference sets of target genes35\n(DrugBank [35], Ruiz et al. [36], ChEMBL [37], DGIdb [38] and STITCH [39]). Overall, we provide an36\nin-depth comparison of all combinations of these approaches, identifying their respective strengths and37\ncaveats.38\n4\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nGWAS\nGWAS p-values\nQTL - GWAS\nGene\nLD Reference\nGene scoring\nGWAS\nMendelian randomization\npQTLs \n- Tissue-wide\n- Whole blood\n- Plasma\nGene p-values\nExomea\nGene burden test\n# variants\nTrait\nGene p-values\nSummary statistics Summary statistics\nRare variants (MAF ≤ 1%) in WES\nConsidered variants:\n - putative loss-of-\n   function\n - missense\nTsum = /uni2211z2\ni\nTsum /uni223C/uni2211/uni03BBi /uni03C72\n1\nProtein\nTranscript\neQTLs \npQTL b\nGWAS b\n/uni03B2MR\n(Causal effect)\neQTL b\nGWAS b\n/uni03B2MR\nGene\n0 1 2\nb\neQTL-GWAS\npQTL-GWAS\nExome\nGWAS\nDGIdb\nSTITCH\nChEMBL\nDrugBank\nRuiz et al.\nChEMBL\nDrug target\ngenes\nPrioritized \ndisease genes\nEnrichment analysis (OR)\nArea under the ROC curve (AUC)\nIndication\nDrug\nc\nNetwork diffusion\nProtein-protein \ninteraction (STRING) \nCo-expression\n(CoXRNAseq) \nCo-expression & \nproteomics (FAVA) \nPrioritized disease gene (GWAS, QTL-GWAS, Exome)\nDrug target gene\nslope = \nnetwork diffusion scores (x3)\nnetwork\ndiffusion scores\nrestart parameter r\n(diffusion strength)\nGene p-values\nGene scores\n5\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nFigure 1: Overview of the analysis workflow. a Three different gene prioritization methods were tested\nin this study. The first one uses GWAS summary statistics as input (GWAS); the second combines\nmolecular QTL and GWAS summary statistics (QTL-GWAS): either expression QTL (eQTL) or protein\nQTL (pQTL) data; the third leverages individual-level whole exome sequencing (WES) data (Exome).\nIn the GWAS method, gene p-values are based on the sum of squared SNP z-scores (T sum) that fol-\nlows a weighted χ2\n1 distribution. The QTL-GWAS method integrates QTL and GWAS summary statistics\nthrough Mendelian randomization (MR). MR causal effect sizes (β MR) are calculated from GWAS and\nmQTL effect sizes (GWAS b and mQTL b, respectively) and gene scores are the corresponding p-\nvalues. The Exome method aggregates rare variants from WES data. Putative loss-of-function and\nmissense variants with minor allele frequencies (MAF) below 1% are collapsed in burden tests which\nresults in gene p-values. The different approaches were benchmarked for their ability to prioritize drug\ntarget genes. b The effect of network diffusion using three different network types and different diffusion\nstrengths (i.e. restart parameter r) was evaluated. Drug target genes may only be prioritized following\nsignal propagation from neighboring disease genes. c Diseases were linked to target genes through\npublic drug databases: first, we used drug-indication information to connect the 30 traits to drugs and\nthen leveraged drug-target information to link the drugs to genes. Prioritized disease genes and cor-\nresponding diffusion scores (obtained via strategies described in panel a and b) were then tested for\noverlap with drug target genes through Fisher’s exact tests resulting in odds ratios (ORs) and through\narea under the receiver operating characteristic curve (AUC) values.\nResults39\nOverview of the analysis40\nIn this study, we calculated gene prioritization scores and tested their ability to identify drug targets41\nacross thirty traits (Figure 1). We focused on three types of methods termed GWAS, QTL-GWAS and42\nExome that allow the computation of gene scores provided genetic association data (Figure 1a).43\n44\nThe GWAS method takes as input GWAS summary statistics together with a matching LD reference45\npanel. Gene p-values are calculated based on the sum of squared test statistics for SNPs falling into46\nthe gene region [9]. The QTL-GWAS methods integrate GWAS summary statistics with molecular QTL47\ndata for the gene of interest. We calculated gene scores using i) expression QTL data (eQTL-GWAS )48\nfrom the largest available whole blood eQTL study (eQTLGen study, n = 31,684) as well as tissue-wide49\neQTL data from the GTEx consortium v8 (n = 65-573 for 48 tissue types) and ii) protein QTL data50\n(pQTL-GWAS) from the largest available plasma pQTL study (deCODE study, n = 35,559) [14] and i.51\nIntegration was done by performing Mendelian randomization (MR) analyses using either the protein52\n6\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nor transcript as exposure and the GWAS trait as outcome. If not specified otherwise, the eQTL-GWAS53\nmethod refers to the tissue-wide analysis in which the eQTLGen and GTEx data are combined by54\nconsidering the tissue for which the MR effect was the most significant (Methods). While the GWAS55\nand QTL-GWAS methods focuse on common genetic variants, the Exome method considers only56\nrare variants from WES data with minor allele frequencies (MAF) below 1%. Gene scores were57\nbased on gene burden tests that aggregate putative loss-of-function and missense variants, and we58\nused the resulting p-values from the WES analysis in the UKBB [25]. To allow for a fair comparison59\nwith the Exome method while also exploiting disease-specific consortia GWAS summary statistics60\nwith maximized case counts, we calculated gene prioritization scores for the GWAS and QTL-GWAS61\nmethods using both consortia GWAS and UKBB GWAS data (Table S1-3; Methods).62\n63\nDisease genes may not coincide with drug target genes, but they may be in close proximity in terms64\nof molecular interaction (Figure 1b). Through diffusion based on random walks, we leveraged network65\nconnectivity to prioritize neighbours of disease genes, which may be drug targets. We tested this66\nhypothesis on three different network types: the STRING PPI network which relies on literature67\ninteractions among other data types [32], a gene co-expression network based on 31,499 RNA-seq68\nsamples (CoXRNAseq ) [33], and gene co-expression network based on single cell RNA-seq and69\nproteomics data (FAVA) [34]. Gene prioritization scores were obtained following diffusion at six different70\nrestart parameter values (r = 0, 0.2, 0.4, 0.6, 0.8, 1) (Methods).71\n72\nDisease drug target genes were defined using public databases. Specifically, drug-disease indica-73\ntion were retrieved from DrugBank [35], Ruiz et al. [36], and ChEMBL [37], while drug-drug target74\npairs originate from DGIdb [38], STITCH [39], and ChEMBL [37]. Drug target enrichment analyses75\nwere calculated for the following five database combinations: DrugBank/DGIdb, DrugBank/STITCH,76\nRuiz/DGIdb, Ruiz/STITCH, and ChEMBL/ChEMBL.77\n78\nFinally, prioritized disease genes, defined as the top 1% of genes identified through the 12 combinations79\n7\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nof gene prioritization and network diffusion methods (5% for combinations involving the pQTL-GWAS80\nmethod to account for the smaller set of testable genes), were then tested for enrichment with the five81\ndrug target genes using Fisher’s exact test (Figure 1c). Background genes were defined as all genes that82\ncould be tested by the respective method, and sensitivity analyses were performed on background genes83\ntestable for all methods. Second, we calculated the area under the receiver operating characteristic84\ncurve (AUC) values which has the advantage of not requiring any thresholds. To compute a combined85\nenrichment score per method, we aggregate results across traits and drug databases termed overall86\nORs or overall AUC values (Methods).87\nConcordance of prioritized genes among gene scoring methods88\nWe first analyzed whether genes prioritized by the GWAS, QTL-GWAS and Exome methods were89\nconcordant (Figure 2). For each of the thirty traits (Figure 2a), we calculated gene scores for the90\ntestable autosomal protein-coding genes (GWAS: ∼19,150, eQTL-GWAS: ∼12,550 (blood) and ∼16,25091\n(tissue-wide), pQTL-GWAS: ∼1,870, Exome: ∼18,800). In the tissue-wide eQTL-GWAS method, the92\ntissue with the most significant MR p-value was selected. In Figure S1, we show the proportion of genes93\nmapped to a particular tissue category. The contribution of glandular-endocrine, neural central nervous94\nsystem (CNS) and whole blood (eQTLGen) tissue categories were the highest (respective means of95\n15.3%, 12.8%, and 12.6% across the thirty traits; Table S4-5). Although each trait had genes mapped96\nto nearly all tissues, a few distinctive patterns could be observed: cardiac muscle tissues contributed97\nthe most to atrial fibrillation (16.4%), vascular tissues the most to coronary artery disease (16.5%)98\nfollowed by diastolic (11.1%) and systolic (9.9%) blood pressure, and the neural CNS contributed the99\nmost to schizophrenia (16.9%) and bipolar disease (16.6%).100\n101\n8\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\n0\n2\n4log−OR\nAlzheimer\nAsthma\nAtopic dermatitis\nAtrial fibrillation\nBipolar\nCAD\nCKD\nCOPD\nDiastolic BP\nEndometriosis\nEpilepsy\nGlaucoma\nIBD\nIBS\nLDL\nMDD\nMultiple sclerosis\nOsteoarthritis\nOsteoporosis\nParkinson's disease\nPneumonia\nPsoriasis\nRheumatoid arthritis\nSchizophrenia\nStroke\nSystolic BP\nT1D\nT2D\nTotal cholesterol\nVTE\n0.0\n2.5\n5.0\n7.5\n10.0\n0.0 2.5 5.0 7.5 10.0\nTop gene percentile (%)\nlog−OR\neQTL−GWAS vs GWAS\n0.0\n2.5\n5.0\n7.5\n10.0\n0.0 2.5 5.0 7.5 10.0\nTop gene percentile (%)\nlog−OR\nGWAS vs Exome\n0.0\n2.5\n5.0\n7.5\n10.0\n0.0 2.5 5.0 7.5 10.0\nTop gene percentile (%)\nlog−OR\neQTL−GWAS vs Exome\n0.0\n2.5\n5.0\n7.5\n10.0\n0.0 2.5 5.0 7.5 10.0\nTop gene percentile (%)\nlog−OR\neQTL−GWAS vs pQTL−GWAS (blood)\nAlzheimer\nAsthma\nAtopic dermatitis\nAtrial fibrillation\nBipolar\nCAD\nCKD\nCOPD\nDiastolic BP\nEndometriosis\nEpilepsy\nGlaucoma\nIBD\nIBS\nLDL\nMDD\nMultiple sclerosis\nOsteoarthritis\nOsteoporosis\nParkinson's disease\nPneumonia\nPsoriasis\nRheumatoid arthritis\nSchizophrenia\nStroke\nSystolic BP\nT1D\nT2D\nTotal cholesterol\nVTE\n0.2\n0.3\n0.4\n0.5\n0.6\n0.7\nQ1 Q2 Q3 Q4\nTranscript Heritability − quartile\nSpearman  ρ\neQTL−GWAS vs GWAS\n0.1\n0.2\n0.3\n0.4\nQ1 Q2 Q3 Q4\nTranscript Heritability − quartile\nSpearman  ρ\neQTL−GWAS vs pQTL−GWAS (blood)\na b\nc d\n9\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nFigure 2: Evaluating the concordance of prioritized genes among methods. a Thirty different traits/drug\nindications were tested in this study. b The top prioritized genes between pairs of methods were com-\npared at different thresholds for each trait (legend shown in a). The logarithm of odds ratios (log-OR)\nwere calculated from Fisher’s exact tests. Log-ORs are only plotted for percentiles at which common\ngenes between pairs of methods were found. Comparisons were conducted on the same background\ngenes and same data origins (i.e., on UK Biobank GWASs for comparisons with the Exome method).\nTissue-wide eQTL-GWAS gene prioritizations were considered for the comparison with the GWAS and\nExome methods, and the blood-only eQTL-GWAS gene prioritization method for the comparison with\nthe pQTL-GWAS method. c Spearman correlations calculated per trait between the gene significance\n(-log10(p-values)) from the GWAS and tissue-wide eQTL-GWAS methods. The analysis was conducted\nper trait on all common genes ( ∼16,100) stratified into quartiles according to transcript heritability (in\ncis). d Spearman correlations calculated per trait between gene Mendelian randomization (MR) causal\neffect sizes (βMR) from the blood eQTL-GWAS and pQTL-GWAS methods. The analysis was conducted\non all common genes (∼1,370) stratified into quartiles according to the transcript heritability. In c and d,\nthe boxplots bound the 25th, 50th (median, centre), and the 75th quantile. Whiskers range from minima\n(Q1 – 1.5 · IQR) to maxima (Q3 + 1.5 · IQR) with points corresponding to individual traits from a.\nThe concordance of prioritized genes among pairs of methods is summarized in Figure 2b. For each102\ntrait, we calculated Fisher’s exact tests between the top prioritized genes at thresholds ranging from the103\ntop 0.1%-10% (Methods). The overlap was the highest between the GWAS and eQTL-GWAS methods.104\nAt 1%, the median odds ratio (OR) was 212.2 which dropped to 51.0 and 22.1 at 5% and 10%, respec-105\ntively. The concordance between GWAS and eQTL-GWAS prioritized genes was highest for transcripts106\nwith high heritabilities (Figure 2c; Methods). Similarly, the agreement between the eQTL-GWAS (whole107\nblood) and pQTL-GWAS (blood plasma) increased with increasing transcript heritabilities (Figure 2d).108\nOverall, the median ORs between these two methods was 8.5 and 4.6 at the top 5% and 10%, respec-109\ntively. The overlap of prioritized genes was the lowest with the Exome method. The top 1% GWAS vs110\nExome and eQTL-GWAS vs Exome overlaps (based only on UKBB GWAS summary statistics), yielded111\nmedian ORs of 1.7 and 1.9, respectively which dropped to 1.0 at 10% for both methods.112\nEnrichment of prioritized genes for drug targets113\nNext, we assessed the extent to which prioritized genes overlapped with drug target genes. For114\neach trait, we conducted enrichment analyses for the GWAS, eQTL-GWAS, pQTL-GWAS and Exome115\nmethods using our five definitions of drug target genes.116\n10\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\n117\nIn Figure 3a, we show the resulting ORs for the DrugBank/DGIdb database combination. Across118\nmethods, genetic support for drug targets was the highest for LDL and total cholesterol (average ORs119\nof 5.99 and 6.12, respectively). Lowest enrichment ratios were obtained for neuro-psychiatric traits120\n(average OR of 1.56) and glaucoma (average OR of 1.14). The average OR across traits was 2.48,121\n2.68, 1.65, and 1.26 for the GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods, respectively.122\nWe explored a range of top disease gene percentiles (0.1-5%) and the corresponding ORs are123\nshown in Figure 3b. Restricting disease genes to the top 0.1% for all methods increased the average124\nORs without changing the method ranking with average ORs of 3.68, 4.02, 2.40, and 1.44 for the125\nGWAS, eQTL-GWAS, Exome and pQTL-GWAS methods, respectively. We further analyzed whether126\nidentified drug targets were the same across methods and found that prioritized drug target genes were127\nsimilar between GWAS and eQTL-GWAS methods (average Jaccard index of 0.39), less so between128\neQTL-GWAS and pQTL-GWAS methods (blood tissues; average Jaccard index of 0.15) and were very129\ndifferent from Exome identified targets (average Jaccard index of 0.06 between GWAS & Exome and130\neQTL-GWAS & Exome methods). Average AUC values across traits were of 53.4%, 51.9%, 50.5% and131\n49.9% for the GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods (Figure 3c).132\n133\nWhile the number of drugs reported per indication was similar across databases (average of 43.9,134\n41.8 and 40.4 for Ruiz et al., ChEMBL and DrugBank, respectively), the average number of reported135\ndrug targets was much higher for Ruiz/STITCH (285), Ruiz/DGIdb (274.8), Drugbank/DGIdb (263.4)136\nand Drugbank/STITCH (244.2) than for ChEMBL/ChEMBL (24.8; Table S7). We repeated drug target137\nenrichment calculations for all drug database combinations (Figure 3d, Figure S2). The average OR138\nfor the GWAS/eQTL-GWAS methods were 2.48/2.68, 2.80/2.53, 2.18/2.12, 1.78/1.61 and 1.78/1.51 for139\nDrugbank/DGIdb, ChEMBL/ChEMBL, Ruiz/DGIdb, Ruiz/STITCH and Drugbank/STITCH, respectively.140\nOverall, the variability in ORs across traits was the highest in the ChEMBL database (Figure 3d, Figure141\nS2), likely due to the low average number of reported drug targets which leads to very high ORs when142\ndrug targets figured among the prioritized genes (e.g. for LDL and total cholesterol), but for many traits143\n11\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\ndrug target genes were not among prioritized genes (e.g. for type 1 diabetes, atopic dermatitis and144\ninflammatory bowel disease).145\n146\nSince enrichment results can differ widely across traits and reference databases, we calculated overall147\nenrichment and AUC values across traits and drug databases, including sensitivity analyses on UKBB148\ndata only and common background genes (Table S9, Figure S4; Methods). The overall ORs were 2.17149\n(UKBB: 1.72), 2.04 (UKBB: 1.67), 1.81 and 1.31 (UKBB: 1.30) for the GWAS, eQTL-GWAS, Exome and150\npQTL-GWAS methods, respectively. There were no significant differences between these four methods151\nin terms of enrichment OR (Pdiff > 0.05 including in the sensitivity analyses). Overall AUCs were 54.3%152\n(UKBB: 52.8%), 52.8% (UKBB: 51.4%), 51.7% and 51.3% (UKBB: 50.6%) for the GWAS, eQTL-GWAS,153\nExome and pQTL-GWAS methods, respectively. Judging by the AUC values, GWAS performed signifi-154\ncantly better than eQTL-GWAS (Pdiff = 3.1e-5) also when only considering testable eQTL genes (P diff =155\n2.9e-4). Significantly higher AUC values were obtained for the GWAS compared to Exome on consortia156\ndata (Pdiff = 2.2e-4) which was no longer the case on UKBB data (P diff = 0.06). The difference between157\neQTL-GWAS and Exome was not significant on either dataset (P diff of 0.12 and 0.77 on consortia and158\nUKBB data, respectively). The number of testable genes was much lower for the pQTL-GWAS method159\n(∼1,870 genes). With this set of background genes, GWAS still scored a higher overall AUC (55.1%,160\nPdiff = 2.1e-3). No difference was observed between the pQTL-GWAS and tissue-wide or whole blood161\neQTL-GWAS methods (Pdiff of 0.66 and 0.87, respectively).162\n12\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\n0.35\n0.40\n0.45\n0.50\n0.55\n0.60\nGWAS eQTL−GWAS Exome pQTL−GWAS\nAUC\n0\n10\n20\n0 1 2 3 4 5\nTop gene percentile (%)\nOR\nGWAS\neQTL−GWAS\nExome\npQTL−GWAS\nPanel a,d*\n*pQTL-GWAS\n1\n8\n64\nDrugBank /\nDGIdb\nRuiz /\nDGIdb\nRuiz /\nSTITCH\nDrugBank /\nSTITCH\nChEMBL /\nChEMBL\nOR\nGlaucoma\nBipolar\nMDD\nSchizophrenia\nAlzheimer\nParkinson's disease\nEpilepsy\nMultiple sclerosis\nPneumonia\nCOPD\nAsthma\nIBS\nIBD\nPsoriasis\nAtopic dermatitis\nOsteoarthritis\nOsteoporosis\nRheumatoid arthritis\nStroke\nAtrial fibrillation\nDiastolic BP\nSystolic BP\nCAD\nVTE\nEndometriosis\nCKD\nT1D\nT2D\nTotal cholesterol\nLDL\neQTL−GWAS vs\nGWAS\nGWAS vs ExomeeQTL−GWAS vs\nExome\neQTL−GWAS vs \npQTL−GWAS (blood)\n1.00 0.75 0.50 0.25 0.00\neQTL−GWAS vs Exome\nGWAS vs Exome\neQTL−GWAS vs pQTL−GWAS\neQTL−GWAS vs GWAS\nEndometriosisRheumatoid arthritis\nOsteoporosisMultiple sclerosis\nParkinson's disease\nTotal cholesterol\nPsoriasisAtrial fibrillation\nGlaucoma\nIBS\nMDDSystolic BP\nLDL\nCKD Diastolic BP\nAsthma\nIBD\nCAD\nT2D\nSchizophrenia\nAtopic dermatitis\nVTE\nOsteoarthritis\nBipolar\nEpilepsy\nCOPDAlzheimer\nPneumonia\nStroke\nT1D\nJaccard index\n1.00\n0.75\n0.50\n0.25\n0.00\nCommon identified drug targets\n1\n4\n2\n1\n0\n4\n3\n4\n2\n7\n5\n4\n1\n4\n4\n7\n0\n0\n2\n0\n1\n0\n3\n2\n2\n1\n6\n4\n3\n7\n11\n10\n0\n2\n4\n1\n2\n1\n2\n2\n5\n2\n5\n9\n2\n1\n2\n1\n6\n3\n8\n11\n2\n5\n8\n9\n6\n2\n4\n10\n4\n2\n4\n4\n1\n5\n6\n6\n10\n12\n18\n18\n5\n9\n0\n8\n4\n3\n7\n8\n6\n10\n14\n16\n8\n13\n20\n17\n5\n7\n11\n13\n5\n7\n4\n7\n0\n0\n1\n1\n1\n2\n4\n6\n1\n2\n1\n1\n6\n8\n9\n10\n6\n15\n13\n13\n6\n13\n13\n14\nGlaucoma\nBipolar\nMDD\nSchizophrenia\nAlzheimer\nParkinson's disease\nEpilepsy\nMultiple sclerosis\nPneumonia\nCOPD\nAsthma\nIBS\nIBD\nPsoriasis\nAtopic dermatitis\nOsteoarthritis\nOsteoporosis\nRheumatoid arthritis\nStroke\nAtrial fibrillation\nDiastolic BP\nSystolic BP\nCAD\nVTE\nEndometriosis\nCKD\nT1D\nT2D\nTotal cholesterol\nLDL\n0 2 4 6 8\nOR\nMetabolicGenito-\nurinaryCirculatory systemMusculoskel. &\nconnect. tissueSkinDigestive\nsystemRespiratoryNervous systemPsychiatricEye\na\n# Identified\ndrug targets\nGWAS\neQTL-GWAS\nExome\npQTL-GWASICD10 \nclassification\nb\nc\neQTL-GWAS & \nGWAS GWAS & Exome\neQTL-GWAS &\nExome\neQTL-GWAS & \npQTL-GWAS (blood)\nJaccard index\n1.000.750.500.250.00\nCommon identified drug targets\nd\n13\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nFigure 3: Enrichment for drug target genes. a Left: Barplot with odds ratios (ORs) calculated from\nFisher’s exact tests between drug target genes and the top 1% (5% for pQTL-GWAS) prioritized genes\nfor the four tested methods and thirty traits, classified according to trait category. Drug target genes were\ndefined by DrugBank/DGIdb, and only drug target genes that could be tested by the respective method\nwere considered. The number on the right of each bar indicates the number of identified drug target\ngenes. Right: Overlap of identified drug target genes between pairs of methods quantified through the\nJaccard index. The blood-only eQTL-GWAS gene prioritization method was used for the comparison\nwith the pQTL-GWAS method. Plots using UKBB GWASs-only are shown in Figure S3. b ORs at\ndifferent top prioritised gene percentiles for the four methods. The plotted dots correspond to the median\nOR across the thirty traits, and the shaded area bounds the 10% and 90% percentiles. c Boxplots\nshowing the area under the receiver operating characteristic curve (AUC) values. AUC values were\ncalculated for each trait as indicated by the points (legend in Figure 2a) and using the same background\ngenes and drug target definitions as in a. d ORs calculated for the five drug target definitions and for\nall four methods (legend in b). The OR was set to 1 for traits with no identified drug target genes. In b\nand d, the boxplots bound the 25th, 50th (median, centre), and the 75th quantile. Whiskers range from\nminima (Q1 – 1.5 · IQR) to maxima (Q3 + 1.5 · IQR) with points outside representing potential outliers.\nExamples of drug target prioritization ranks163\nIn Figure 4, we highlight drug targets and their gene prioritization ranks for a few examples (complete list164\nin Table S10). Major antihypercholesterolemic drug targets PCSK9 (evolocumab, alirocumab), HMGCR165\n(statins) and NPC1L1 (ezetimibe) were top ranked by all methods (except for no pQTLs being available166\nfor HMGCR and NPC1L1; Figure 4a). HCN4, the target of antiarrhythmic drug dronedarone, was priori-167\ntized as a disease gene for atrial fibrillation only through the GWAS method. Although highly expressed168\nin the atrial appendage and left ventricle of the heart, no eQTL was reported for this gene (Figure 4b).169\nSeveral antiepileptic drugs target SCN1A which was highly prioritized by the GWAS and eQTL-GWAS170\nmethods with the strongest MR effect found in the nucleus accumbens (basal ganglia) of the brain (Fig-171\nure 4c). Antiplatelet drug dipyrimadole used in the prevention and treatment of vascular diseases such172\nas stroke and coronary artery disease is listed to target 23 genes of the PDE superfamily in ChEMBL.173\nOf these, four (PDE4D, PDE3A, PDE3B, PDE6B) were ranked in the top 1% by the exome method for174\nstroke (Figure 4d). None of the other methods prioritized any of these 23 genes. For coronary artery dis-175\nease, another superfamily member (PDE5A) had a low ranking (< 2%) for the GWAS and QTL-GWAS176\nmethods, supported by solid GWAS and e/pQTL colocalisation (Figure 4e).177\n14\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nda\nb\nDipyri-\ndamole\nDrone-\ndarone\nPCSK9\n HMGCR\nPDE3B\nPDE4D\nNPC1L1\nHCN4\nStrokeLDL\nAtrial \nfibrillation\n25 (0.15%)\n18 (0.92%)\n1 (<0.01%)\n1-52 (<0.01%)\n1-52 (<0.01%)\n12 (0.07%)\nno pQTL\n10 (0.05%)\n53 (0.33%)\nNA\n5 (0.03%)\n175 (0.92%)\nno eQTL\neQTL-GWAS\nNA\npQTL-GWAS\n9,010 (47.9%)\nExome\n12 (0.06%)\nGWAS\nArtery - Aorta\nArtery - Coronary\nArtery - Tibial\nBrain - Amygdala\nBrain - Ant. cing. cortex\nBrain - Caudate (basal ganglia)\nBrain - Cerebellar Hemisphere\nBrain - Cerebellum\nBrain - Cortex\nBrain - Frontal Cortex (BA9)\nBrain - Hippocampus\nBrain - Hypothalamus\nBrain - Nuc. acc. (basal ganglia)\nBrain - Putamen (basal ganglia)\nBrain - Spinal cord (cervical c-1)\nBrain - Substantia nigra\nHeart - Atrial Appendage\nHeart - Left Ventricle\nPituitary\nTestis\nWhole Blood\n0\n10\n20\n30\n40\nTPM\nBulk tissue gene expression for HCN4\n> 18%\n > 12%\nno pQTL / NA\n< 1%\nc\nSCN1AEpilepsy\n13 (0.08%)\nno pQTL\n472 (2.5%)\n2 (<0.01%)\ne\nBrain − basal ganglia\nBrain − cortex\nBrain cerebellum\nTestis\n−0.025 0.000 0.025 0.050\nMR effect size\nPosition on chrom 4 [Mb]\n−log10(PGWAS)\n0 2 4 6 8 10\nPosition on chrom 4 [Mb]\n−log10(PpQTL)\n0 20 40 60 80 100 120\nPosition on chrom 4 [Mb]\n−log10(PeQTL)\n0 10 20 30 40 50\n120.0 120.2 120.4 120.6 120.8\nPosition on chrom 4 [Mb]\nPosition on chr 4 [Mb]\n0\n5\n10\n15\n− log10(p−value)\n0\n20\n40\n60\n80\n100\nRecombination rate (cM/Mb)\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF\n/uni25CF/uni25CF/uni25CF\n/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF/uni25CF\n/uni25CF\nrs7678555\n0.2\n0.4\n0.6\n0.8\nr2\nMYOZ2\nUSP53\nC4orf3\nFABP2\nLINC01061\nLOC645513\nPDE5A\nLINC01365 MAD2L1\n120 120.2 120.4 120.6 120.8 121\nPosition on chr4 (Mb)\nPlotted SNPs\nPDE5ACAD\n150 (0.9%)\n30 (1.6%)\n7,212 (38.3%)\n 285 (1.5%)Dipyri-\ndamole\n> 5%\n> 1%\n> 1%\n> 1%\nPDE3A\n PDE6B\n15\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nFigure 4: Examples illustrating drug target genes and their prioritization ranks. a Three drug target\ngenes (PCSK9 (evolocumab, alirocumab), HMGCR (statins) and NPC1L1 (ezetimibe) shown in purple)\nfor LDL cholesterol (blue box) and their prioritization ranks (top percentiles shown in parentheses) of\neach of the four methods (GWAS in green, eQTL-GWAS in yellow, Exome in blue and pQTL-GWAS\nin red). Genes that were not testable by a given method are reported as NA (no e/pQTL means that\nthe gene was measured, but had no QTL) and a range of ranks (i.e., 1-52) indicates tied p-values. b\nTop plot shows the prioritization ranks of HCN4, the target of antiarrhythmic drug, dronedarone. Bot-\ntom plot shows the gene expression profile of HCN4 across GTEx tissues (transcript per million - TPM)\nwith “Testis”, “Heart – Atrial Appendage” and “Heart – Left Ventricle” dominating.c Top plot shows the\nprioritization ranks of SCN1A (Sodium Voltage-Gated Channel Alpha Subunit 1), a drug target gene of\nseveral antiepileptic drugs. Bottom plot shows Mendelian randomization (MR) effects (red dot) wih 95%\nCI (black bars) across tissues in which there was a significant eQTL. d Antiplatelet drug dipyrimadole\nand gene prioritization ranks of its multiple drug targets (a non-exhaustive selection) of the phosphodi-\nesterase (PDE) superfamily. e Top plot shows the gene prioritization ranks of PDE5A, another reported\ntarget for dipyrimadole. Bottom plot shows the regional SNP associations (-log 10(p-values)) with coro-\nnary artery disease (CAD; GWAS, green), PDE5A protein (pQTL, red) and PDE5A transcript (eQTL,\nyellow), respectively (red dashed lines indicate the significance thresholds of the respective SNP asso-\nciation, and grey shade marks the position of PDE5A). Bottom row illustrates the positions and strand\ndirection of the genes in the locus.\nHeritability and polygenicity of drug target transcripts and proteins178\nIt has been shown that drug target genes are more likely to have lower residual variance intolerance179\nscores (RVIS), i.e., are less tolerant to change [1]. With the availability of large-scale eQTL and pQTL180\ndata, we tested whether drug target transcript or protein levels may be less impacted by genomic181\nvariations.182\n183\nTo this end, we compared cis-heritabilities and polygenicities of drug target genes versus non-drug184\ntarget genes that were measured in the respective studies (i.e., also those with no reported e/pQTLs;185\nMethods). We conducted the analysis per trait and for each of the five drug target gene definitions.186\nOverall, we observed that drug target genes were less heritable and more polygenic than non-drug187\ntarget genes pointing towards a negative selection [40] (Figure S5). This trend was less pronounced188\nfor tissue-wide than for whole blood eQTLs, and was the strongest for pQTLs. Across QTL studies and189\ndrug databases, the traits for which drug targets were significantly less heritable and more polygenic190\ndiffered substantially. However, in no scenario drug target genes were more heritable than non-drug191\ntarget genes on either the transcript or protein-level (at a nominally significant level). Considering drug192\n16\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\ntarget genes defined by DrugBank/DGIdb for the plasma protein QTLs as an example: targets for traits193\nfrom the circulatory system were all shown to be more polygenic, and targets for psychiatric traits were194\nall less heritable at a nominally significant level.195\nNetwork diffusion196\nFinally, we assessed whether network diffusion can identify drug target genes for which there is no197\ndirect genetic evidence. Gene scores from prioritization methods defined the initial distribution p0 of198\nthe diffusion process. This process is regulated by a restart parameter r where lower values result in a199\nwider diffusion (i.e., genes can be prioritized even when distant from initial disease genes; Methods).200\nThe stationary distribution was calculated for six different restart parameters, ranging from no diffusion201\n(r = 1) to complete diffusion (r = 0). Since the set of testable proteins ( ∼1,870) is enriched for drug202\ntarget genes (two-sided binomial test: p-value = 1.3e-47 for DrugBank/DGIdb; complete results in Table203\nS15; Methods) AUC values were artificially inflated upon projecting the gene scores onto the network204\nand pQTL-GWAS results are hence not discussed.205\n206\nApplying diffusion using the STRING network massively boosted the overlap between the diffused207\nprioritized genes and the drug target genes (Figure 5a-b, Figure S6-7). At no diffusion, overall AUC208\nvalues across the thirty traits were 54.3%, 52.8% and 51.7% for the GWAS, eQTL-GWAS and Exome209\nmethods, respectively, which increased to 68.9%, 67.7% and 66.9% at r = 0.6, and 73.5%, 72.9% and210\n72.3% at r = 0.4 (Figure 5a, Figure S6, Table S12). The same trend was observed when calculating211\nenrichment scores for the top 1% genes with overall ORs of 4.63, 5.21 and 5.07 at r = 0.4 (Figure 5b,212\nFigure S7, Table S12). On the other hand, improvements were modest when considering co-expression213\nnetworks. At r = 0.6, overall AUC values increased to 54.9%, 54.7% and 53.5% in case of the214\nCoXRNAseq network. Although small, the difference was significant compared to no diffusion (P diff of215\n5.11e-3, 4.12e-14 and 4.83e-5, respectively). Overall ORs at r = 0.6 were 2.28, 2.04 and 1.91 which216\nwere not significantly different (P diff > 0.05) compared to no diffusion. Likewise, in the FAVA network,217\noverall AUC values at r = 0.6 were 55.9%, 54.2% and 53.6% (Pdiff compared to no diffusion of 2.23e-5,218\n17\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\n3.08e-3 and 7.3e-6), and ORs 2.38, 2.02 and 1.77 (P diff > 0.05) for GWAS, eQTL-GWAS and Exome219\nmethods, respectively (Figure S6-7, Table S12-13).220\n221\nWe further assessed which method’s AUC values benefited the most from network diffusion. To allow222\nfair comparisons with the Exome methods, we used UKBB GWAS data for the GWAS and eQTL-GWAS223\nmethods. Across all diffusion parameters r, overall AUC values were significantly higher for GWAS224\nthan eQTL-GWAS in the STRING and FAVA network (P diff < 4.45e-4), but not any different in the225\nCoXRNAseq network (P diff > 0.05). A nominally significant difference in favour of GWAS compared226\nto Exome was only observed in the STRING network at r values of 0.4, 0.6 and 0.8 (P diff of 0.0262,227\n7.36e-3 and 0.0146, respectively). No statistical differences were observed between the eQTL-GWAS228\nand Exome method except for a nominally significant difference in favour of eQTL-GWAS at r = 0.2 in229\nthe CoXRNAseq network (Pdiff = 0.0113).230\n231\nWhen investigating the network connectivity, we observed that drug target genes were significantly more232\nlikely to be hub genes (Figure 5c, Figure S8). This observation was particularly strong in the STRING233\nnetwork (mean log-degree = 13.0 vs 12.3, Pdiff = 6.6e-284 for DrugBank/DGIdb), but also present in the234\nco-expression networks (∆ log-degree = 0.064, Pdiff = 0.011 for CoXRNAseq; ∆ log-degree = 0.3, Pdiff235\n= 6.6e-11 for FAVA). As a consequence, the network’s node degree was found to be a good predictor236\nof drug targets, and the best performance was found for the network degree in STRING (overall AUC =237\n77.6%, overall OR = 8.71). Given this bias, we generated random initial disease gene scores and de-238\ntermined to which extent genetically-informed p0 distributions performed better compared to random p0239\ndistributions. Although GWAS, eQTL-GWAS and Exome methods had significantly higher AUC values240\nthan random score distributions for any givenr value in the STRING network (Pdiff < 1.62e-7; Table S13),241\nthe performance of a mildly diffused (r= 0.8) random score (which is unaware of the target disease) per-242\nformed significantly better than any disease gene prioritisation method without diffusion (Pdiff of 4.18e-6,243\n3.58e-10 and 2.10e-12 compared to GWAS, eQTL-GWAs and Exome, respectively). In line with this244\nobservation, the network degree was still significantly better than gene prioritization methods at r = 0.2245\n18\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\n(Pdiff of 8.98e-6, 9.87e-13 and 1.89e-11 compared to GWAS, eQTL-GWAs and Exome, respectively).246\n0.5\n2.0\n8.0\n1 0.8 0.6 0.4 0.2 0\nrestart parameter r\nOR\nSTRING\n0.5\n2.0\n8.0\n1 0.8 0.6 0.4 0.2 0\nrestart parameter r\nOR\nCoXRNAseq\n0.5\n1.0\n2.0\n4.0\n8.0\n1 0.8 0.6 0.4 0.2 0\nrestart parameter r\nOR\nFAVA\nGWAS eQTL−GWAS Exome pQTL−GWAS Random\n0\n1000\n2000\n7.5 10.0 12.5 15.0\nlog−degree\nGene count\nSTRING ; ∆ = 0.75 ; p = 6.6e−284\n0\n500\n1000\n1500\n2 4 6 8\nlog−degree\nGene count\nCoXRNAseq ; ∆ = 0.064 ; p = 0.011\n0\n200\n400\n600\n7 9 11 13\nlog−degree\nGene count\nFAVA ; ∆ = 0.3 ; p = 6.6e−11\nDrug target gene\n no yes\n0.4\n0.5\n0.6\n0.7\n0.8\n1 0.8 0.6 0.4 0.2 0\nrestart parameter r\nAUC\nSTRING\n0.4\n0.5\n0.6\n0.7\n0.8\n1 0.8 0.6 0.4 0.2 0\nrestart parameter r\nAUC\nCoXRNAseq\n0.4\n0.5\n0.6\n0.7\n0.8\n1 0.8 0.6 0.4 0.2 0\nrestart parameter r\nAUC\nFAVA\nGWAS eQTL−GWAS Exome pQTL−GWAS Random\na\nb\nNo diffusion Network\ndegree\nNo diffusion Network\ndegree\nc\n19\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nFigure 5: Effect of network diffusion to prioritize drug target genes. a Boxplots showing the area under\nthe receiver operating characteristic curve (AUC) values for each network type (STRING, CoXRNAseq\nand FAVA) and method at different restart parameter values r. AUC values were calculated for each\nof the thirty traits, and drug target genes were defined by DrugBank/DGIdb. At an r value of 1 (no\nnetwork diffusion), the analysis corresponds to the results in Figure 3b, and at an r value of 0, the gene\nprioritization rank is simply based on the degree of the network nodes. At r < 1, the background genes\nare the genes reported in the respective network. The star next to the pQTL-GWAS method signals that\nthe set of testable genes for this method is enriched for drug target genes and therefore higher AUC\nvalues were obtained when adding background genes with zero-valued initial scores. b Odds ratios\n(ORs) between prioritized genes (top 1%) and drug target genes for each network type and method at\ndifferent r values across the thirty traits (same drug target and background genes as in a). The OR was\nset to 1 for traits with no identified drug target genes. c Histograms showing the degree distribution of\ndrug target genes and non-drug target genes in each network. The difference in log-degree (∆) and the\np-values from two-sided t-tests are shown in the titles. In a and b, the boxplots bound the 25th, 50th\n(median, centre), and the 75th quantile. Whiskers range from minima (Q1 – 1.5 · IQR) to maxima (Q3 +\n1.5 · IQR) with points above or below representing potential outliers.\nExamples of prioritized genes through network diffusion247\nIn the following, we describe several examples for which drug targets figured among the top 1% genes248\nonly after network diffusion (complete list in Table S14). Amyloid-beta precursor protein (APP) targeted249\nby the monoclonal antibody aducanumab in the treatment of Alzheimer’s disease was ranked 506 (top250\n2.7%) prior and 152 (top 0.8%) after diffusion on the STRING network (r = 0.6; Figure 6a) based on the251\neQTL-GWAS method. Prioritization was largely influenced by its interacting neighbour Apolipoprotein E252\n(APOE) which was the top 5 ranked gene for Alzheimer’s disease. Tumor necrosis factor (TNF), a drug253\ntarget in the treatment of inflammatory diseases such as psoriasis, was ranked 1,558 (top 8%; Exome-254\nPsoriasis) prior and 182 (top 0.98%; r = 0.6) post-propagation in the STRING network (Figure 6b).255\nWhile initially the drug target F2 (Coagulation Factor II, Thrombin) for VTE (venous thromboembolism)256\nranked only in the top 2% it moved up to the top 1% regardless of the network used for diffusion at r =257\n0.6 (top 0.9%, 0.6% and 0.7% for STRONG, CoXRNAseq and FAVA, respectively). In the STRING and258\nCoXRNAseq networks, this boost could largely be attributed to the interacting fibrinogen genes (FGA,259\nFGB and FGG) that ranked in the top 0.06% (Figure 6c).260\n20\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nAPP\nNCSTN\nAPH1A\nPSEN1\nAPBA2\nAPBB1\nBACE1\nAPBA1\nSORL1\nAPOE NAE1\nFGB\nFGA\nAHSG\nUGT2B10\nF2 ITIH2\nAPOH\nSLC17A2\nC8A\nAPOA2\nALB\nFGB\nFGA\nAHSG\nUGT2B10\nF2 ITIH2\nAPOH\nSLC17A2\nC8A\nAPOA2\nALB\nC4A\nC4B\nITIH4\nITIH2 F12\nC7\nF2\nVTN\nSERPINF2\nPLG\nKNG1\nC4A\nC4B\nITIH4\nITIH2 F12\nC7\nF2\nVTN\nSERPINF2\nPLG\nKNG1\nF2\nFGG\nFGB\nFGA\nTHBD\nSERPINC1\nSERPIND1\nF2R\nF2RL3\nCPB2\nF2RL2\nF2\nFGG\nFGB\nFGA\nTHBD\nSERPINC1\nSERPIND1\nF2R\nF2RL3\nCPB2\nF2RL2\na b\nc\nr = 1\nr = 0.6\nVTE\nSTRING CoXRNAseq FAVA\nGWAS\nr = 0.6\nr = 1\nSTRING\neQTL-GWAS\n Exome\nPsoriasis\nSTRING\nr = 1\nr = 0.6\nTNF\nTNFRSF1A RIPK1\nTRADD\nTNFRSF1B\nTRAF2\nF ADD\nIKBKB\nIL10\nIL6\nIL4\nTNF\nTNFRSF1A RIPK1\nTRADD\nTNFRSF1B\nTRAF2\nF ADD\nIKBKB\nIL10\nIL6\nIL4\nAPP\nNCSTN\nAPH1A\nPSEN1\nAPBA2\nAPBB1\nBACE1\nAPBA1\nSORL1\nAPOE NAE1\n1.2e−05 4.5e−04\n1.2e−05 2.5e−03\nAlzheimer\n7.5e−06 2.8e−03\n21\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nFigure 6: Examples illustrating network diffusion to prioritize drug target genes. a Top ten network\nneighbours of drug target APP (brown circle) and their prioritization values (i.e., normalized node proba-\nbilities) of the eQTL-GWAS method for Alzheimer’s disease are shown before (r= 1) and after diffusion\n(r = 0.6) on the STRING network. b Same representation as in a showing Exome prioritization values\nfor psoriasis and tumor necrosis factor (TNF) drug target. c Top ten network neighbours of drug target\nF2 (Coagulation Factor II, Thrombin) in the STRING, CoXRNAseq and FAVA networks. GWAS prioriti-\nzation values for venous thromboembolism (VTE) are shown before (r = 1) and after diffusion (r = 0.6)\non each network. In each network example (a-c), the drug target gene was among the top 1% prioritized\ngenes only after diffusion at r = 0.6.\nDiscussion261\nWe conducted a comprehensive benchmarking between different genetically informed approaches262\n(GWAS, QTL-GWAS and Exome) combined with network diffusion to prioritize drug target genes.263\nThe strength of our analysis lies in the side-by-side comparison of gene prioritization methods that264\nindividually have proven to be successful in identifying drug targets. Recently, methods have emerged265\nthat combine multiple genetic predictors to derive an aggregate score often using machine-learning266\ntechniques [27, 41, 42]. These scores demonstrated high enrichment for drug targets but reveal little267\nabout underlying molecular mechanisms. Our aim was to disentangle the importance of the choice of268\nthe ground truth (i.e., drug target genes), the input data (such as molecular QTLs, WES) in combination269\nwith different molecular networks to highlight added benefits while also exposing weaknesses compared270\nto using GWAS data alone.271\n272\nAdjusting for differences in background genes and data origins, GWAS yielded higher AUC than273\neQTL- and pQTL-GWAS, but no significant difference was found with Exome. Genes prioritized by274\nthe Exome method were different from those identified by the GWAS and QTL-GWAS methods which275\nwas also reflected in the identified drug targets. While this could imply that rare- and common variant276\ngenetic architectures are complementary, differences could also be due to power issues. Possibly,277\nwith increased sample size the implicated genes will converge, but the extent to which they can be278\nperturbed by regulatory vs rare coding variants might remain different. Considering ORs, we lacked279\nstatistical power to claim significant differences between methods since the number of drug targets280\n22\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\namong top 1% prioritized genes can be very low. Overall enrichment ORs for drug targets were 2.17,281\n2.04, 1.81 and 1.31 for the GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods, respectively.282\nAlthough ORs for the pQTL-GWAS method may seem lower, it should be noted that testable proteins283\n(i.e., proteins with pQTLs) accounted for ∼10% of GWAS testable genes. On the same background284\ngenes, ORs for the tissue-wide and blood-only eQTL-GWAS methods were 1.38 and 1.22, respectively.285\nFor the AUC metric, no significant difference between eQTL-GWAS and pQTL-GWAS was found. In286\nthe method comparisons, we considered multiple drug target gene definitions. The number of targets287\nper drug drastically differed between ChEMBL and the DGIdb or STITCH databases due to differences288\nin their construct. Drug target genes in the ChEMBL database are manually curated and should not289\ncontain false positives but it remains debatable whether to consider only primary or also secondary290\ntarget genes. For instance, ChEMBL only lists HMGCR as a drug target for statins, whereas the DGIdb291\ndatabase also includes APOA5, APOB and APOE among others. For this reason, we considered292\ndifferent databases and present enrichment results for both broad and narrow drug target definitions,293\nas well as aggregates.294\n295\nNetwork diffusion was beneficial for prioritizing drug target genes with weaker genetic support. A296\nremarkable increase in drug target identification was achieved when using the STRING network.297\nHowever, this improvement may be due to a circularity in the data generation process leading to drug298\ntargets being much more likely to also be hub genes. Although genetically-informed methods performed299\nbetter than random distributions, the STRING network node degrees resulted in the highest AUC values300\noverall. Thus, care has to be taken when relying on literature-derived gene-gene interactions as ag-301\ngressive diffusion will point to the same drug target genes, irrespective of the disease, and the intrinsic302\nbias stemming from under- and over-studied genes may hinder the discovery of new drug targets.303\nThe improvements made with co-expression networks, which do not suffer from publication/curation304\nbiases, were minor in comparison. Although significant with the AUC metric, ORs were not significantly305\nincreased with a diffusion of r = 0.6 as compared to no diffusion for any of the methods.306\n307\n23\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nAmong the set of measured proteins (which itself was enriched for drug target genes), protein levels of308\ndrug target genes exhibited lower heritabilities and higher polygenicities than non-drug target genes.309\nThe same trend, but to a lesser extent, was observed on the transcript level. Additionally, drug target310\ngenes had stronger network connections than non-drug target genes, even in unbiased co-expression311\nnetworks. Together, these observations suggest a tendency for drug targets to be evolutionary312\nconstrained and as a result are more protected from genomic perturbations.313\n314\nSeveral limitations should be considered. First, we do not take into account directionality of therapeutic315\nand genetic effects, i.e., whether the drug is an agonist or antagonist. Although found to be less316\nperformant than GWAS, QTL-GWAS methods have the advantage of specifying directionality, as317\nopposed to gene scores from the GWAS approach which ignores SNP effect directions. Second, the318\nused molecular QTL data sets cover only a small fraction of possible intermediate traits through which319\nSNPs exert their disease-inducing effects [43]. Third, we only focus on common genetic variants when320\nassociating transcript and protein levels. With the advent of coupled rare variant-protein level data,321\neither from populations enriched for rare variants or sequencing data [14, 44], more powerful QTL-322\nGWAS methods are likely to emerge that combine mechanistic insights gained from QTL approaches323\nwhile capturing rare variant associations previously missed. Fourth, drug target data are sparse which324\nlimits the statistical power in benchmarking analyses. Given the required resources to test a drug325\ntarget in clinical settings, focusing on top ranking genes is of most interest. This scenario is best326\ndescribed with a threshold that defines highly prioritized genes for enrichment analyses. However,327\nROC curves that quantify the performance at all prioritization thresholds (i.e. use all data at hand)328\nwere better powered to detect subtle differences between methods. Finally, our analysis compares329\nmethods using historical drug discovery data as the ground truth. This data is highly biased with330\nG-protein-coupled receptors being targets of a third of FDA-approved drugs [45]. Many other genes331\nmay be effective targets, but have never been tested in clinical trials. Thus, our results may not reflect332\nhow well the tested genetic approaches uncover true disease genes, but rather how well they identify333\ntargets that were historically prioritized in drug development processes. Since the emergence of robust334\n24\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nGWAS, more and more clinical trials are motivated by genetically informed targets. Thus, drug tar-335\nget databases will tend to overlap better with GWAS-inspired genes, leading to artificially higher overlap.336\n337\nTo conclude, we systematically evaluated major gene prioritization approaches for their ability to identify338\napproved drug target genes. Our analyses highlight the power of harnessing multiple data sources339\nby capitalizing on QTLs for mechanistic insights, sequencing data for rare variant associations, GWAS340\nwhen molecular QTL signals are missing and network propagation to leverage gene-gene interactions.341\nMethods342\nGWAS data343\nWe used the largest (to-date), publicly available GWAS summary statistics for each analyzed condi-344\ntion (Table S1). GWAS data came mostly from consortia specific to the respective disease, and were345\noften a meta-analysis comprising the UKBB. Twenty-four out of the 30 conditions were case/control346\nstudies, the remaining 6 being continuous traits: diastolic and systolic blood pressure (DBP and SBP , re-347\nspectively [46]), low-density lipoprotein and total cholesterol (LDL and TC, respectively [47]), estimated348\nglomerular filtration rate (eGFR [48]) and heel bone mineral density ([47]) proxying chronic kidney dis-349\nease (CKD) and osteoporosis, respectively. For four traits with low case count in the UK Biobank (<350\n20,000; chronic obstructive pulmonary disease (COPD), endometriosis, pneumonia and psoriasis) and351\nno large-scale GWAS meta-analysis available, we performed a meta-analysis between the UK Biobank352\n[47] and FinnGen [49] using METAL [50].353\nGWAS gene scores354\nWe used PascalX [9, 51] to compute gene scores based on GWAS summary statistics. The software355\ntakes as input GWAS p-values, gene annotations and LD structure. SNPs are assigned to genes and356\ntheir squared z-scores are summed. This sum, under the null, was shown to follow a weighted chi-357\nsquare distribution with weights being defined by the local LD structure from which gene p-values can be358\nderived [9]. We applied PascalX with default parameters (gene ± 50 kB) on protein-coding genes using359\n25\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nthe Ensembl identifiers and annotations (Ensembl GRCh37.p13 version) and the UK10K reference panel360\n[52]. Across traits, ∼19,150 protein-coding genes could be tested which were ranked by their PascalX361\np-value.362\nMolecular QTL-GWAS gene scores363\nWe integrated molecular quantitative trait loci (QTL) and GWAS summary statistics using Mendelian364\nrandomization (MR) implemented in the smr-ivw software [53, 22]. The exposure (transcript or protein365\nlevels) and outcome disease were instrumented with independent genetic variants, also called instru-366\nmental variables (IVs; r2 < 0.01) and used to calculate putative causal effect estimates of the exposure367\non the outcome (β MR). IVs were required to be strongly associated to the exposure (P QTL < 1e-6) and368\nhad to pass the Steiger filter ensuring no significantly stronger effect on the outcome than on the ex-369\nposure [54]. We used expression QTLs (eQTLs) from the eQTLGen consortium [13] (whole blood; n =370\n31,684) and tissue-specific QTLs from the GTEx v8 release [55] (European ancestry; n = 65-573 for 48371\ntissue types; Table S4) to estimate causal transcript-trait effects. In the eQTLGen dataset there were372\n∼12,550 protein-coding genes with at least 1 IV which increased to ∼16,250 when integrating the GTEx373\ndataset. MR results from both datasets (whole blood from eQTLGen and 49 tissues from GTEx) were374\naggregated by considering the MR causal effect with the lowest p-value across tissues (Table S4-5).375\nProtein QTLs (pQTLs) from the deCODE study [14] (whole blood; n = 35,559) were used to estimate376\nprotein-trait causal effects with ∼1,870 proteins having at least 1 IV. Prior to the analysis, e/pQTL and377\nGWAS data were harmonized, palindromic SNPs were removed as well as SNPs with an allele frequency378\ndifference > 0.05 between datasets. All transcripts and proteins were mapped to Ensembl identifiers as379\nprovided by eQTLGen, GTEx and deCODE.380\nExome gene scores381\nWe used gene burden test results computed on WES data from the UK Biobank [25]. We extracted382\ngene-trait associations based on putative loss of function (pLOF) and deleterious missense variants383\nwith MAF <1% (M3.1 nomenclature in original publication) with phenotypes matching the investigated384\nconditions as indicated in Table S2. Associations were provided for ∼18,800 genes which were ranked385\n26\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nby the association p-value and retrieved by the provided Ensembl identifier.386\nConcordance of gene scoring methods387\nWe tested whether prioritized genes were similar or dissimilar between pairs of methods. First, only388\ngenes (based on Ensembl identifiers) that were common between the two tested methods were selected389\ninto the gene background. Then, prioritized genes were defined at different top percentile cut-offs (0.1%,390\n0.2%, 0.5%, 1%, 2%, 3%, 5%, 7.5%, 10%). The enrichment of prioritized genes between methods was391\nquantified by a Fisher’s exact test using common genes as background genes. When calculating median392\nORs, ORs of traits for which no prioritized genes overlapped at a given percentile were set to 1.393\nDrug target genes394\nWe extracted drug target genes from public resources by combining drug-indication and drug-target links395\nfrom various databases. A given disease/indication was linked to a drug if the drug was indicated to be396\nprescribed for the selected indication and subsequently, the target genes of these drugs were extracted.397\nFor drug-indication pairs we consulted DrugBank, Ruiz et al. and ChEMBL:398\n• DrugBank 5.0 [35] (download: May 2022): DrugBank indications are manually curated from drug399\nlabels and underwent an expert review process. Drug indications have their own DrugBank condi-400\ntion numbers and drugs their DrugBank identifiers.401\n• Ruiz et al. [36]: A drug-disease dataset was created by querying multiple sources such as the402\nDrug Repurposing Database, the Drug Repurposing Hub, and the Drug Indication Database and403\nextracting information from drug labels, DrugBank and the American Association of Clinical Tri-404\nals Database. Drug–disease pairs were filtered for FDA-approved treatment relationships. This405\ndataset uses NLM UMLS CUIDS identifiers (National Library of Medicine -Unified Medical Lan-406\nguage System Controlled Unique Identifier) for diseases and DrugBank identifiers for drugs.407\n• ChEMBL [37] (download: May 2022): ChEMBL drug indications are extracted from multiple408\nsources including DailyMed package inserts, Anatomical Therapeutic Chemical (ATC) classifica-409\ntion and ClinicalTrials.gov. Mapping of disease terms to Medical Subject Headings (MeSH) vocab-410\n27\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nulary and the Experimental Factor Ontology (EFO) is done through a combination of text-mining,411\nautomated mapping and manual curation/validation. Drugs are reported with ChEMBL identifiers.412\nThe mapping of GWAS traits to the drug indication identifiers of the respective database is shown in413\nTable S6.414\n415\nDrug target genes were extracted from the DGIdb, STITCH and ChEMBL databases:416\n• Drug Gene Interaction database (DGIdb) 4.0 [38] (release: January 2021): Aggregated drug-gene417\ninteractions from multiple sources including DrugBank, Drug Target Commons, the Therapeutic418\nTarget Database and Guide to Pharmacology. Genes were matched to Ensembl identifiers using419\nthe provided gene vocabulary file. Drugs were reported through DrugBank or ChEMBL identifiers,420\nand mapping from ChEMBL to DrugBank identifiers was done with UniChem [56], using PubChem421\nIDs as intermediates.422\n• Search Tool for Interacting CHemicals (STITCH) 5.0 [39]: Aggregated drug-protein interaction423\ndata from high-throughput experiments data, manually curated datasets and prediction methods.424\nOnly high confidence drug-protein relationships (confidence score ≥ 700) of the type “inhibition”425\nand “activation” were considered. STITCH uses PubChem Chemical Identifiers (CID) for drugs426\nand mapping to DrugBank IDs was done through the chemical sources file provided by STITCH.427\nProtein Ensembl identifiers were mapped to gene Ensembl identifiers using biomaRt (GRCh37,428\nv2.50.3)[57].429\n• ChEMBL [37] (download: May 2022): ChEMBL provides drug targets which have been manually430\ncurated from literature. Drug targets are identified by ChEMBL IDs with mapping to UniProt Ac-431\ncessions provided by ChEMBL. UniProt identifiers were then mapped to gene Ensembl identifiers432\nthrough the UniProt REST API [58].433\nIn this analysis we considered drug target genes resulting from the following combinations: Drug-434\nBank/DGIdb, DrugBank/STITCH, Ruiz/DGIdb, Ruiz/STITCH, and ChEMBL/ChEMBL. The number of435\ndrugs and drug target genes per indication is shown in Table S7.436\n28\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nDrug target enrichment and AUC calculations437\nEnrichment for drug target genes was calculated through two-sided Fisher’s exact tests. A contingency438\ntable was constructed based on testable genes (i.e., background genes), with genes categorized439\ninto prioritized (top 1% or 5% for the pQTL-GWAS) and drug target genes. In rare instances (i.e.,440\npQTL-GWAS background genes and ChEMBL/ChEMBL drug targets) where diagonal values were 0,441\nthese were changed to 1. If no prioritized gene coincided with a drug target gene, the resulting OR442\nwas set to 1 (for visualization purposes this was not done in barplots where each trait was shown443\nindividually). AUC values and standard errors were calculated using the R package pROC v1.15.3 [59].444\n445\nLog-OR and AUC values (both are denotedbi herein) were aggregated across traits and drug databases446\n(m = 30 · 5 = 150 observations per method) as follows:447\n¯b = 1\nm\nmX\ni\nbi (1)\nwith corresponding variance:448\nvar(¯b) = 1′ · S · R · S · 1/m2 (2)\nwhere S is a diagonal matrix of size mxm containing standard errors of bi and R is the correlation449\nmatrix between drug databases and traits. This matrix was derived from the Kronecker product of the450\ndrug database correlation matrix and phenotypic trait correlation matrix (Table S8). The drug database451\ncorrelation matrix was derived on the gene level (i.e., 1 if the gene was a drug target for any of the 30452\ntraits, 0 if not) and the phenotypic trait correlation on individual-level data from the UKBB (codes in Table453\nS2). ¯b was referred to as the overall AUC/ log-OR (overall OR after an exponential transformation).454\n455\nTo calculate the statistical difference of ¯b1 and ¯b2 for method 1 and 2, respectively, we derived the456\nvariance of the difference as follows:457\n29\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nvar(¯b1 − ¯b2) = var(¯b1) + var(¯b2) − 2 · cov(¯b1,¯b2) (3)\nwith cov(¯b1,¯b2) ≈ r ×\n\n1′ · S1 · R · S2 · 1/m2\u0001\n, where r is the empirical correlation between b1 and b2.458\nFrom the resulting z-score, a two-sided p-value was calculated.459\nTranscript and protein level heritabilities and polygenicity460\nTranscript and protein level heritabilities were estimated from QTL effects. Standardized QTL effects461\n( ˆβG) were approximated by dividing SNP z-scores by the square root of the sample size. The corre-462\nsponding variance (var( ˆβG)) equals the inverse of the sample size. The cis heritability (ˆh2\ncis) could then463\nbe estimated by summing up effects of independent (r 2 < 0.01) and significant (p-value < 1e-6) QTLs464\nin proximity of the transcript/protein (± 500 kB) while taking into account their variance:465\nˆh2\ncis =\nX\ni\n\u0010\nˆβ2\nGi − var(ˆβGi)\n\u0011\n(4)\nProtein heritabilities were based on the deCODE plasma protein dataset [14] and transcript heritabilities466\nfor whole blood on the eQTLGen dataset [13]. Tissue-wide transcript heritabilities were based on eQTL467\neffects from the tissue in which the MR effect was the most significant [55].468\n469\nTo calculate the difference in heritabilities and polygenicities between drug target and non-drug target470\ngenes, we considered all transcripts and proteins measured in the respective study which were classified471\naccordingly. Per trait, the difference in heritability was then calculated through a two-sided t-test. For472\nthe polygenicity analysis, we considered the number of independent (r2 < 0.01) and significant (p-value473\n< 1e-6) QTLs associated to a transcript/protein. Note that this proxy for polygenicity is biased, as474\nfor less heritable omics entities we have less power to detect the independent signals, and may look475\nless polygenic. We then conducted two-sided Wilcoxon tests to determine the difference in number of476\ninstrumental variables (IVs). Heritability and polygenicity tests were only performed for traits with at477\nleast three drug targets within the respective set of measured transcripts/proteins. Note that in case a478\n30\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\ntranscript or protein was reported as measured in the study, but had no associated QTL, its heritability479\nand number of IVs were set to zero.480\nNetworks481\nTo calculate network diffusion scores, we used the following three networks:482\n• Search Tool for Retrieval of Interacting Genes/Proteins (STRING) v11 [32]: The protein-protein483\n(PPI) interaction network results from predictions based on genomic context information, co-484\nexpression, text-mining, experimental biochemical/genetic data and curated databases (curated485\npathways and protein-complex knowledge). Protein Ensembl identifiers were mapped to gene En-486\nsembl identifiers using biomaRt (GRCh37, v2.50.3)[57]. We use interaction confidence scores as487\nedge weights.488\n• CoXRNAseq [33]: This network was constructed by first performing a principal component analy-489\nsis on the gene co-expression correlation matrix of 31,499 RNA-seq samples. Reliable principal490\ncomponents were retained from which the final network was constructed via Pearson correlations.491\nWe filtered pairwise interactions to only retain those with z-scores above 4. Genes were reported492\nwith Ensembl identifiers and z-scores were used as edge weights.493\n• Functional Associations using Variational Autoencoders (FAVA) [34]: This network is based on494\nsingle cell RNA-seq read-count data from the Human Protein Atlas and proteomics data from the495\nPRoteomics IDEntifications (PRIDE) database. First, the high-dimensional expression data was496\nreduced into a latent space using variational autoencoders. From this latent space, the network497\nwas derived via pairwise Pearson correlations. Each reported interaction has a score which we498\nuse as edge weight (final network reports interactions with scores above 0.15). Protein Ensembl499\nidentifiers were mapped to gene Ensembl identifiers using biomaRt.500\nA summary of network properties is given in Table S11. In all analyses, we use weighted networks, and501\nwe refer to weighted node degrees (i.e., sum of edge weights linking the node of interest to adjacent502\nnodes) as node degrees.503\n31\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nNetwork diffusion504\nWe calculated network diffusion scores based on Markov random walks. Starting from an initial node505\ndistribution p0, a stationary distribution is calculated based on network connectivity. This diffusion pro-506\ncess depends on a restart parameter r which determines how often the random walker returns to the507\ninitial values. Analytically, the stationary distribution (p∞) is given by:508\np∞ = (I − (1 − r) · W )−1 · p0 (5)\nwhere W is the column-normalized weighted adjacency matrix and I the identity matrix of the same509\ndimension as W [60]. The initial node distribution p0 was determined by the squared z-scores derived510\nfrom the gene p-values (normalized to sum up to 1). Genes that could not be tested by a given method511\nhad their initial value set to 0. Additionally, we tested the performance of network diffusion on random512\ninitial distributions p0. For each trait, a random distribution was generated which all were different, but513\nconsistent across analyses. Resulting network diffusion scores p∞ were ranked for AUC calculations,514\nand the top 1% scored genes were used in the enrichment analyses.515\n516\nNetwork manipulations, visualization and degree calculations were performed with the R igraph package517\nv1.3.5 [61].518\nEnrichment of available proteins for drug targets519\nWe conducted binomial tests to verify whether the set of testable (i.e., at least 1 pQTL) and measured520\nproteins ( ∼1,870 and ∼4,450, respectively) were enriched for drug target genes. We performed the521\nanalysis on each of the five drug target definitions and proceeded as follows: 1) we extracted the number522\nof testable/measured proteins that are drug targets (“number of successes”), 2) considering all protein-523\ncoding autosomal genes (19,430), we extracted those that are drug targets (“number of trials”), 3) we524\ndetermined the proportion of testable/measured proteins among all protein-coding genes (“expected525\nprobability of success”). From these numbers, we conducted two-sided exact binomial tests (Table526\n32\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nS15).527\nData availability\nWhole blood expression QTLs are from the eQTLGen eQTL meta-analysis and are available at https:\n//www.eqtlgen.org/cis-eqtls.html. Tissue-wide expression QTLs are from the GTEx project and\nare available at https://gtexportal.org/home/datasets. Plasma protein QTLs are from the de-\nCODE study and are available at https://www.decode.com/summarydata/. Summary statistics from\nwhole exome gene burden tests are available in the GWAS Catalog (accession IDs are in Table S2).\nGenetic and phenotypic data from the UK Biobank Resource are available to approved researchers.\nGWAS summary statistics from the UK Biobank are available athttp://www.nealelab.is/uk-biobank\nand https://pan.ukbb.broadinstitute.org. GWAS summary statistics from FinnGen are available at\nhttps://www.finngen.fi/en/access_results. GWAS summary statistics for multiple sclerosis (MS)\nare available by application from https://imsgc.net/?page_id=31. Full list of GWAS summary statis-\ntics used in this study is in Table S1-3, all of which are publicly available. UK10K individual-level data\nare available upon request (https://www.uk10k.org/data_access.html).\nCode availability\nGWAS calculations were performed with REGENIE which is available athttps://github.com/rgcgithub/\nregenie. GWAS meta-analyses were performed with METAL which is available at https://github.\ncom/statgen/METAL. Gene scoring was performed with the PascalX software which is available at\nhttps://github.com/BergmannLab/PascalX. QTL Mendelian randomization analyses were performed\nwith the SMR-IVW software which is available at https://github.com/masadler/smrivw.\nCompeting interests\nThe authors declare that they have no competing interests.\n33\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nAuthors’ contributions\nMCS and ZK conceived and designed the study. MCS performed statistical analyses. PD provided\nguidance on statistical analyses. ZK supervised all statistical analyses. CA contributed to the collection\nand interpretation of pharmacological and biological data. All the authors contributed by providing advice\non interpretation of results. MCS and ZK drafted the manuscript. All authors read, approved, and\nprovided feedback on the final manuscript.\nAcknowledgements\nThis work was supported by the Swiss National Science Foundation (310030\n189147) to Z.K. This re-\nsearch has been conducted using the UK Biobank Resource under Application Number 16389. LD\nwas calculated based on the UK10K data resource (EGAD00001000740, EGAD00001000741). Com-\nputations we performed on the JURA cluster of the University of Lausanne. We also would like to\nacknowledge the participants and investigators of the UK Biobank and FinnGen study. We thank Daniel\nKrefl for his help and support in implementing the PascalX software and Liza Darrous for critical reading\nof the draft.\nReferences\n[1] Matthew R Nelson, Hannah Tipney, Jeffery L Painter, Judong Shen, Paola Nicoletti, Yufeng Shen,\nAris Floratos, Pak Chung Sham, Mulin Jun Li, Junwen Wang, et al. The support of human genetic\nevidence for approved drug indications. Nature genetics, 47(8):856–860, 2015.\n[2] Emily A King, J Wade Davis, and Jacob F Degner. Are drug targets with genetic support twice as\nlikely to be approved? revised estimates of the impact of genetic support for drug mechanisms on\nthe probability of drug approval. PLoS genetics, 15(12):e1008489, 2019.\n[3] Stacey L Edwards, Jonathan Beesley, Juliet D French, and Alison M Dunning. Beyond gwass:\nilluminating the dark road from association to function. The American Journal of Human Genetics,\n93(5):779–797, 2013.\n34\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\n[4] Chen Cao and John Moult. Gwas and drug targets. BMC genomics, 15(4):1–14, 2014.\n[5] Vivian Tam, Nikunj Patel, Michelle Turcotte, Y ohan Boss´e, Guillaume Par´e, and David Meyre. Bene-\nfits and limitations of genome-wide association studies. Nature Reviews Genetics, 20(8):467–484,\n2019.\n[6] Steven Gazal, Omer Weissbrod, Farhad Hormozdiari, Kushal K Dey, Joseph Nasser, Karthik A\nJagadeesh, Daniel J Weiner, Huwenbo Shi, Charles P Fulco, Luke J O’Connor, et al. Combining\nsnp-to-gene linking strategies to identify disease genes and assess disease omnigenicity. Nature\nGenetics, pages 1–10, 2022.\n[7] Jimmy Z Liu, Allan F Mcrae, Dale R Nyholt, Sarah E Medland, Naomi R Wray, Kevin M Brown,\nNicholas K Hayward, Grant W Montgomery, Peter M Visscher, Nicholas G Martin, et al. A versatile\ngene-based test for genome-wide association studies. The American Journal of Human Genetics,\n87(1):139–145, 2010.\n[8] Christiaan A de Leeuw, Joris M Mooij, Tom Heskes, and Danielle Posthuma. Magma: generalized\ngene-set analysis of gwas data. PLoS computational biology, 11(4):e1004219, 2015.\n[9] David Lamparter, Daniel Marbach, Rico Rueedi, Zolt ´an Kutalik, and Sven Bergmann. Fast and\nrigorous computation of gene and pathway scores from snp-based summary statistics. PLoS com-\nputational biology, 12(1):e1004714, 2016.\n[10] John Lonsdale, Jeffrey Thomas, Mike Salvatore, Rebecca Phillips, Edmund Lo, Saboor Shad,\nRichard Hasz, Gary Walters, Fernando Garcia, Nancy Y oung, et al. The genotype-tissue expres-\nsion (gtex) project. Nature genetics, 45(6):580–585, 2013.\n[11] Benjamin B Sun, Joseph C Maranville, James E Peters, David Stacey, James R Staley, James\nBlackshaw, Stephen Burgess, Tao Jiang, Ellie Paige, Praveen Surendran, et al. Genomic atlas of\nthe human plasma proteome. Nature, 558(7708):73–79, 2018.\n[12] Lasse Folkersen, Stefan Gustafsson, Qin Wang, Daniel Hvidberg Hansen, ˚Asa K Hedman, Andrew\nSchork, Karen Page, Daria V Zhernakova, Y ang Wu, James Peters, et al. Genomic and drug target\n35\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nevaluation of 90 cardiovascular proteins in 30,931 individuals. Nature metabolism, 2(10):1135–\n1148, 2020.\n[13] Urmo V ˜osa, Annique Claringbould, Harm-Jan Westra, Marc Jan Bonder, Patrick Deelen, Biao Zeng,\nHolger Kirsten, Ashis Saha, Roman Kreuzhuber, Harm Brugge, et al. Large-scale cis-and trans-\neqtl analyses identify thousands of genetic loci and polygenic scores that regulate blood gene\nexpression. Nature genetics, pages 1–11, 2021.\n[14] Egil Ferkingstad, Patrick Sulem, Bjarni A Atlason, Gardar Sveinbjornsson, Magnus I Magnusson,\nEdda L Styrmisdottir, Kristbjorg Gunnarsdottir, Agnar Helgason, Asmundur Oddsson, Bjarni V Hall-\ndorsson, et al. Large-scale integration of the plasma proteome with genetics and disease. Nature\nGenetics, 53(12):1712–1721, 2021.\n[15] Benjamin B Sun, Joshua Chiou, Matthew Traylor, Christian Benner, Yi-Hsiang Hsu, Tom G Richard-\nson, Praveen Surendran, Anubha Mahajan, Chloe Robins, Steven G Vasquez-Grinnell, et al. Ge-\nnetic regulation of the human plasma proteome in 54,306 uk biobank participants. BioRxiv, 2022.\n[16] Claudia Giambartolomei, Damjan Vukcevic, Eric E Schadt, Lude Franke, Aroon D Hingorani, Chris\nWallace, and Vincent Plagnol. Bayesian test for colocalisation between pairs of genetic association\nstudies using summary statistics. PLoS Genet, 10(5):e1004383, 2014.\n[17] Farhad Hormozdiari, Martijn Van De Bunt, Ayellet V Segre, Xiao Li, Jong Wha J Joo, Michael Bilow,\nJae Hoon Sul, Sriram Sankararaman, Bogdan Pasaniuc, and Eleazar Eskin. Colocalization of gwas\nand eqtl signals detects target genes.The American Journal of Human Genetics, 99(6):1245–1260,\n2016.\n[18] Alexander Gusev, Arthur Ko, Huwenbo Shi, Gaurav Bhatia, Wonil Chung, Brenda WJH Penninx,\nRick Jansen, Eco JC De Geus, Dorret I Boomsma, Fred A Wright, et al. Integrative approaches for\nlarge-scale transcriptome-wide association studies. Nature genetics, 48(3):245–252, 2016.\n[19] Alvaro N Barbeira, Scott P Dickinson, Rodrigo Bonazzola, Jiamao Zheng, Heather E Wheeler,\nJason M Torres, Eric S Torstenson, Kaanan P Shah, Tzintzuni Garcia, Todd L Edwards, et al.\n36\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\nExploring the phenotypic consequences of tissue specific gene expression variation inferred from\ngwas summary statistics. Nature communications, 9(1):1–20, 2018.\n[20] Y ang Wu, Jian Zeng, Futao Zhang, Zhihong Zhu, Ting Qi, Zhili Zheng, Luke R Lloyd-Jones, Ric-\ncardo E Marioni, Nicholas G Martin, Grant W Montgomery, et al. Integrative analysis of omics\nsummary data reveals putative mechanisms underlying complex traits. Nature communications,\n9(1):1–14, 2018.\n[21] Eleonora Porcu, Sina R ¨ueger, Kaido Lepik, Federico A Santoni, Alexandre Reymond, and Zolt ´an\nKutalik. Mendelian randomization integrating gwas and eqtl data reveals genetic determinants of\ncomplex and clinical traits. Nature communications, 10(1):1–12, 2019.\n[22] Marie C Sadler, Chiara Auwerx, Kaido Lepik, Eleonora Porcu, and Zolt ´an Kutalik. Quantifying the\nrole of transcript levels in mediating dna methylation effects on complex traits and diseases.Nature\nCommunications, 13(1):1–14, 2022.\n[23] Elizabeth T Cirulli, Simon White, Robert W Read, Gai Elhanan, William J Metcalf, Francisco Tanud-\njaja, Donna M Fath, Efren Sandoval, Magnus Isaksson, Karen A Schlauch, et al. Genome-wide\nrare variant analysis for thousands of phenotypes in over 70,000 exomes from two cohorts. Nature\ncommunications, 11(1):1–10, 2020.\n[24] Jack A Kosmicki, Julie E Horowitz, Nilanjana Banerjee, Rouel Lanche, Anthony Marcketta, Evan\nMaxwell, Xiaodong Bai, Dylan Sun, Joshua D Backman, Deepika Sharma, et al. Pan-ancestry\nexome-wide association analyses of covid-19 outcomes in 586,157 individuals. The American\nJournal of Human Genetics, 108(7):1350–1355, 2021.\n[25] Joshua D Backman, Alexander H Li, Anthony Marcketta, Dylan Sun, Joelle Mbatchou, Michael D\nKessler, Christian Benner, Daren Liu, Adam E Locke, Suganthi Balasubramanian, et al. Exome\nsequencing and analysis of 454,787 uk biobank participants. Nature, 599(7886):628–634, 2021.\n[26] Emre Guney, J ¨org Menche, Marc Vidal, and Albert-L ´aszl´o Bar´abasi. Network-based in silico drug\nefficacy screening. Nature communications, 7(1):1–13, 2016.\n37\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\n[27] Hai Fang, Hans De Wolf, Bogdan Knezevic, Katie L Burnham, Julie Osgood, Anna Sanniti, Alicia\nLled´o Lara, Silva Kasela, Stephane De Cesco, J ¨org K Wegner, et al. A genetics-led approach\ndefines the drug target landscape of 30 immune-related traits. Nature genetics, 51(7):1082–1091,\n2019.\n[28] Aidan MacNamara, Nikolina Nakic, Ali Amin Al Olama, Cong Guo, Karsten B Sieber, Mark R Hurle,\nand Alex Gutteridge. Network and pathway expansion of genetic disease associations identifies\nsuccessful drug targets. Scientific reports, 10(1):1–11, 2020.\n[29] Yingnan Han, Clarence Wang, Katherine Klinger, Deepak K Rajpal, and Cheng Zhu. An integrative\nnetwork-based approach for drug target indication expansion. PloS one, 16(7):e0253614, 2021.\n[30] Inigo Barrio-Hernandez, Jeremy Schwartzentruber, Anjali Shrivastava, Noemi del Toro, Qian\nZhang, Glyn Bradley, Henning Hermjakob, Sandra Orchard, Ian Dunham, Carl A Anderson, et al.\nNetwork expansion of genetic associations defines a pleiotropy map of human cell biology.BioRxiv,\n2021.\n[31] Katja Luck, Dae-Kyum Kim, Luke Lambourne, Kerstin Spirohn, Bridget E Begg, Wenting Bian, Ruth\nBrignall, Tiziana Cafarelli, Francisco J Campos-Laborie, Benoit Charloteaux, et al. A reference map\nof the human binary protein interactome. Nature, 580(7803):402–408, 2020.\n[32] Damian Szklarczyk, Annika L Gable, David Lyon, Alexander Junge, Stefan Wyder, Jaime Huerta-\nCepas, Milan Simonovic, Nadezhda T Doncheva, John H Morris, Peer Bork, et al. String v11:\nprotein–protein association networks with increased coverage, supporting functional discovery in\ngenome-wide experimental datasets. Nucleic acids research, 47(D1):D607–D613, 2019.\n[33] Patrick Deelen, Sipko van Dam, Johanna C Herkert, Juha M Karjalainen, Harm Brugge, Kristin M\nAbbott, Cleo C van Diemen, Paul A van der Zwaag, Erica H Gerkes, Evelien Zonneveld-Huijssoon,\net al. Improving the diagnostic yield of exome-sequencing by predicting gene–phenotype associa-\ntions using large-scale gene expression analysis. Nature communications, 10(1):1–13, 2019.\n38\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\n[34] Mikaela Koutrouli, Pau Piera L ´ındez, Robbin Bouwmeester, Lennart Martens, and Lars Juhl\nJensen. Fava: High-quality functional association networks inferred from scrna-seq and proteomics\ndata. bioRxiv, 2022.\n[35] David S Wishart, Y annick D Feunang, An C Guo, Elvis J Lo, Ana Marcu, Jason R Grant, Tanvir\nSajed, Daniel Johnson, Carin Li, Zinat Sayeeda, et al. Drugbank 5.0: a major update to the\ndrugbank database for 2018. Nucleic acids research, 46(D1):D1074–D1082, 2018.\n[36] Camilo Ruiz, Marinka Zitnik, and Jure Leskovec. Identification of disease treatment mechanisms\nthrough the multiscale interactome. Nature communications, 12(1):1–15, 2021.\n[37] Anna Gaulton, Anne Hersey, Michał Nowotka, A Patricia Bento, Jon Chambers, David Mendez,\nPrudence Mutowo, Francis Atkinson, Louisa J Bellis, Elena Cibri ´an-Uhalte, et al. The chembl\ndatabase in 2017. Nucleic acids research, 45(D1):D945–D954, 2017.\n[38] Sharon L Freshour, Susanna Kiwala, Kelsy C Cotto, Adam C Coffman, Joshua F McMichael,\nJonathan J Song, Malachi Griffith, Obi L Griffith, and Alex H Wagner. Integration of the drug–\ngene interaction database (dgidb 4.0) with open crowdsource efforts. Nucleic acids research,\n49(D1):D1144–D1151, 2021.\n[39] Damian Szklarczyk, Alberto Santos, Christian Von Mering, Lars Juhl Jensen, Peer Bork, and\nMichael Kuhn. Stitch 5: augmenting protein–chemical interaction networks with tissue and affinity\ndata. Nucleic acids research, 44(D1):D380–D384, 2016.\n[40] Luke J O’Connor, Armin P Schoech, Farhad Hormozdiari, Steven Gazal, Nick Patterson, and\nAlkes L Price. Extreme polygenicity of complex traits is explained by negative selection. The\nAmerican Journal of Human Genetics, 105(3):456–476, 2019.\n[41] Edward Mountjoy, Ellen M Schmidt, Miguel Carmona, Jeremy Schwartzentruber, Gareth Peat, Al-\nfredo Miranda, Luca Fumis, James Hayhurst, Annalisa Buniello, Mohd Anisul Karim, et al. An\nopen approach to systematically prioritize causal variants and genes at all published human gwas\ntrait-associated loci. Nature Genetics, 53(11):1527–1533, 2021.\n39\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\n[42] Vincenzo Forgetta, Lai Jiang, Nicholas A Vulpescu, Megan S Hogan, Siyuan Chen, John A Morris,\nStepan Grinek, Christian Benner, Dong-Keun Jang, Quy Hoang, et al. An effector index to predict\ntarget genes at gwas loci. Human Genetics, pages 1–17, 2022.\n[43] Douglas W Y ao, Luke J O’Connor, Alkes L Price, and Alexander Gusev. Quantifying genetic effects\non disease mediated by assayed gene expression levels. Nature Genetics, 52(6):626–633, 2020.\n[44] Ryan S Dhindsa, Oliver S Burren, Benjamin B Sun, Bram P Prins, Dorota Matelska, Eleanor\nWheeler, Jonathan Mitchell, Erin Oerton, Ventzislava A Hristova, Katherine R Smith, et al. Influ-\nences of rare protein-coding genetic variants on the human plasma proteome in 50,829 uk biobank\nparticipants. bioRxiv, 2022.\n[45] Alexander S Hauser, Sreenivas Chavali, Ikuo Masuho, Leonie J Jahn, Kirill A Martemyanov, David E\nGloriam, and M Madan Babu. Pharmacogenomics of gpcr drug targets.Cell, 172(1-2):41–54, 2018.\n[46] Evangelos Evangelou, Helen R Warren, David Mosen-Ansorena, Borbala Mifsud, Raha Pazoki,\nHe Gao, Georgios Ntritsos, Niki Dimou, Claudia P Cabrera, Ibrahim Karaman, et al. Genetic anal-\nysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nature\ngenetics, 50(10):1412–1425, 2018.\n[47] Clare Bycroft, Colin Freeman, Desislava Petkova, Gavin Band, Lloyd T Elliott, Kevin Sharp, Allan\nMotyer, Damjan Vukcevic, Olivier Delaneau, Jared O’Connell, et al. The UK Biobank resource with\ndeep phenotyping and genomic data. Nature, 562(7726):203–209, 2018.\n[48] Matthias Wuttke, Y ong Li, Man Li, Karsten B Sieber, Mary F Feitosa, Mathias Gorski, Adrienne Tin,\nLihua Wang, Audrey Y Chu, Anselm Hoppmann, et al. A catalog of genetic loci associated with\nkidney function from analyses of a million individuals. Nature genetics, 51(6):957–972, 2019.\n[49] Mitja I Kurki, Juha Karjalainen, Priit Palta, Timo P Sipil ¨a, Kati Kristiansson, Kati Donner, Mary P\nReeve, Hannele Laivuori, Mervi Aavikko, Mari A Kaunisto, et al. Finngen: Unique genetic insights\nfrom combining isolated population and national health register data. medRxiv, 2022.\n40\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\n[50] Cristen J Willer, Yun Li, and Gonc ¸alo R Abecasis. Metal: fast and efficient meta-analysis of\ngenomewide association scans. Bioinformatics, 26(17):2190–2191, 2010.\n[51] Daniel Krefl and Sven Bergmann. Bergmannlab/pascalx: Pascalx v0.0.1 (v0.0.1), 2021. https:\n//doi.org/10.5281/zenodo.4429922.\n[52] UK10K et al. The UK10K project identifies rare variants in health and disease. Nature,\n526(7571):82, 2015.\n[53] Zhihong Zhu, Futao Zhang, Han Hu, Andrew Bakshi, Matthew R Robinson, Joseph E Powell,\nGrant W Montgomery, Michael E Goddard, Naomi R Wray, Peter M Visscher, et al. Integration\nof summary data from gwas and eqtl studies predicts complex trait gene targets. Nature genetics,\n48(5):481–487, 2016.\n[54] Gibran Hemani, Kate Tilling, and George Davey Smith. Orienting the causal relationship between\nimprecisely measured traits using GWAS summary data. PLoS genetics, 13(11):e1007081, 2017.\n[55] THE GTEX CONSORTIUM. The GTEx Consortium atlas of genetic regulatory effects across hu-\nman tissues. Science, 369(6509):1318–1330, 2020.\n[56] Jon Chambers, Mark Davies, Anna Gaulton, Anne Hersey, Sameer Velankar, Robert Petryszak,\nJanna Hastings, Louisa Bellis, Shaun McGlinchey, and John P Overington. Unichem: a unified\nchemical structure cross-referencing and identifier tracking system. Journal of cheminformatics,\n5(1):1–9, 2013.\n[57] Steffen Durinck, Paul T. Spellman, Ewan Birney, and Wolfgang Huber. Mapping identifiers for\nthe integration of genomic datasets with the r/bioconductor package biomart. Nature Protocols,\n4:1184–1191, 2009.\n[58] Andrew Nightingale, Ricardo Antunes, Emanuele Alpi, Borisas Bursteinas, Leonardo Gonzales,\nWudong Liu, Jie Luo, Guoying Qi, Edd Turner, and Maria Martin. The proteins api: accessing key\nintegrated protein and genome information. Nucleic acids research, 45(W1):W539–W544, 2017.\n41\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint \n\n[59] Xavier Robin, Natacha Turck, Alexandre Hainard, Natalia Tiberti, Fr´ed´erique Lisacek, Jean-Charles\nSanchez, and Markus M ¨uller. proc: an open-source package for r and s+ to analyze and compare\nroc curves. BMC bioinformatics, 12(1):1–8, 2011.\n[60] Hanghang Tong, Christos Faloutsos, and Jia-Yu Pan. Fast random walk with restart and its appli-\ncations. In Sixth international conference on data mining (ICDM’06), pages 613–622. IEEE, 2006.\n[61] Gabor Csardi, Tamas Nepusz, et al. The igraph software package for complex network research.\nInterJournal, complex systems, 1695(5):1–9, 2006.\n42\n . CC-BY 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)\nThe copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint","source_license":"CC-BY-4.0","license_restricted":false}